2011 Company News

• Zymeworks Inc. Announces Collaboration with Merch to Develop Bi-specific Antibody Therapeutics (Aug. 29)
  
• Immunovaccine Announces 2011 Second Quarter Results (Aug.24)
  
• CO2 Solution Commends Australian Government Announcement to Put Price on Carbon Pollution (Jul.12)
  
• iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals (June 24)
• Immunovaccine Announces Immune Results from Phase I Trial for DPX-0907 Therapeutic Cancer Vaccine (June 1)
• Kane Biotech Awarded Contract by the United States Army to Develop Antibiofilm-Antimicrobial Wound Gel (May 31)
  
• YM BioSciences Announces Orphan Drug Designation for JAK1/JAK2 Inhibitor CYT387 in Europe (May 31)
  
• CARDIOME REPORTS FIRST QUARTER RESULTS (May 16)
  
• ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2011 (May 16)
  
• OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2011 and Provides Update on Plans for the Phase 3 Prostate Cancer SATURN Clinical Trial (May 9) 
  
• Oncolytics Biotech® Inc. Announces Phase I Multiple Myeloma Cancer Study (May 10) 
  
• Oncolytics Biotech® Inc. Enters into Commercial Supply Agreement with SAFC® (May 11) 
  
• Bioniche Life Sciences Inc. Reports Fiscal 2011 Third Quarter Results (May 11) 
  
• YM BioSciences Reports Fiscal Third Quarter 2011 Operational and Financial Results (May 11) 
  
• Oncolytics Biotech® Inc. Announces First Quarter 2011 Results (May 12) 
  
• Trillium raises funds to advance urology program into clinical trials (May 12) 
  
• AMORFIX ANNOUNCES NEW PATENTS AWARDED FOR MISFOLDED SOD1 TARGETS (May 13) 
  
• Microbix Announces Proof-of-Concept Demonstration for LumiSort™ — its Livestock Semen Sexing Technology (May 4)
• Animal Health and Food Safety Vaccine Manufacturing Centre Officially Opens in Belleville, Ontario, Canada (Apr.29)
• RECORD NUMBER OF QUEBECERS PARTICIPATE IN QUIT TO WIN! CHALLENGE (Apr.29)
  
• Health Canada Approves VIMOVO, the First NSAID-PPI Combination to Treat Osteoarthritis Pain and Inflammation While Reducing the Risk of NSAID-associated Ulcers (Apr.27)
• MICROBIX WINS EUROPEAN PATENT PROTECTION FOR VIRUSMAX™, ITS VACCINE PRODUCTION TECHNOLOGY THAT DRAMATICALLY INCREASES YIELDS (Apr.26)
  
• Immunovaccine Reports 2010 Year End Results (Apr.20)
  
• CO2 SOLUTION'S CEO TO BE INTERVIEWED ON BUSINESS NEWS NETWORK (Apr.14)
  
• Immunovaccine Announces Resignation of President and Chief Executive Officer (Apr.14)
  
• Immunovaccine Reports Positive Interim Data from Phase I Clinical Trial of DPX-0907in Patients with Breast, Ovarian and Prostate Cancer (Apr.11)
  
• Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test that Turns Emissions into Beneficial Commercial Products (Apr.7)
  
• CANGENE REORGANIZES WORKFORCE IN ITS CANADIAN OPERATIONS TO INCREASE EFFICIENCY (Apr.7)
  
• Court Sanctions Angiotech's Second Amended and Restated CCAA Plan of Compromise or Arrangement (Apr.7)
  
• Medicago announces research collaboration for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company (Apr.6)
  
• Immunovaccine Presents at Two International Scientific Conferences (Apr.4)
  
• Angiotech Pharmaceuticals, Inc. Announces Amendments to Articles in connection with Implementation of CCAA Plan of Compromise or Arrangement (Apr.3)
  
• Immunovaccine Announces Issuance of Common Shares to a Consultant (Apr.1)
• Immunovaccine Announces Issuance of Common Shares to a Consultant (Apr.1)
  
• Oncolytics Biotech® Inc. to Present at 10th Annual Needham Healthcare Conference (Mar.31)
  
• Lignol provides update on market developments and commercialization plans (Mar.31)
  
• Folltropin®-V - a Key Bioniche Animal Health Product - Receives Marketing Authorization in China (Mar.31)
• SEMBIOSYS ANNOUNCES 2010 FINANCIAL AND OPERATIONAL RESULTS (Mar.31)
  
• Lignol Reports Fiscal 2011 Third Quarter Financial Results (Mar.30)
  
• Angiotech Pharmaceuticals, Inc. Extends Exchange Offer for Senior Floating Rate Notes (Mar.30)
  
• MEDICAGO ANNOUNCES 2010 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS (Mar.30)
  
• Aboriginal students from 37 schools across the country qualify for BDC's E-Spirit business plan competition finals (Mar.29)
  
• OncoGenex to Present at the Needham & Company 10th Annual Healthcare Conference (Mar.29)
  
• 23-year-old donates US$1-million to support University of Waterloo student entrepreneurs (Mar.29)
  
• Aeterna Zentaris Announces Two Poster Presentations on Lead Anticancer Compound Perifosine at Upcoming American Association for Cancer Research Annual Meeting (Mar.28)
  
• Chronic Obstructive Pulmonary Disease (COPD) continues to add to burden in Canada's hospitals (Mar.25)
  
• LOBLAW AND THE UNIVERSITY OF GUELPH ANNOUNCE INAUGURAL CHAIR IN SUSTAINABLE FOOD PRODUCTION (Mar.25)
  
• DC and CFDC: A winning partnership, beneficiary for entrepreneurs in Lanaudière (Mar.24)
  
• Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers (Mar.24)
  
• Aeterna Zentaris Awarded Grant by German Government to Develop Novel Targeted Anti-Cancer Compounds (Mar.24)
  
• Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine (Mar.24)
  
• Medicago commences U.S. phase I clinical testing of its H1N1 / seasonal vaccine (Mar.21)
  
• Immunovaccine Receives $2.9M from ACOA (Mar.21)
  
• CANGENE TO HOST SECOND QUARTER FISCAL 2011 CONFERENCE CALL ON FRIDAY, MARCH 18, 2011 AT 11:00 A.M. EASTERN (Mar.17)
  
• BDC enhances partnership with Canadian Youth Business Foundation (Mar.17)
• Lignol provides update on Cellulosic Ethanol project with Novozymes (Mar.17)
• NEW ONLINE RESOURCE HELPS PATIENTS MAKE THE MOST OF THEIR SECOND CHANCE FOLLOWING A HEART ATTACK OR HEART PROCEDURE (Mar.17)
  
• Oncolytics Biotech® Inc. Announces 2010 Year End Results (Mar.17)
  
• ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2010 (Mar.16)
• CANGENE RECEIVES APPROVAL TO EARLY-ADOPT INTERNATIONAL FINANCIAL REPORTING STANDARDS (Mar.16)
• Aeterna Zentaris to Announce Fourth Quarter and Full Year 2010 Financial and Operating Results on March 22, 2011 (Mar.16)
  
• CO2 Solution Names Thom Skinner Chief Financial Officer (Mar.16)
  
• Medicago USA receives second milestone payment of $3.8 million from the U.S. Department of Defense (Mar.15)
  
• Aeterna Zentaris to Make Oral Presentation on Targeted Inhibitors for PI3K and Erk at Cancer Conference in Berlin (Mar.15)
  
• CARDIOME TO PRESENT AT THE BARCLAYS CAPITAL 2011 GLOBAL HEALTHCARE CONFERENCE (Mar.15)
  
• CO2 Solution Obtains a $250,000 Refundable Contribution from the Federal Government (Mar.14)
  
• Medicago to present at the 23rd annual Roth OC growth stock conference (Mar.14)
  
• OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2010 and Provides Update on Custirsen Clinical Development Program (Mar.10)
  
• Cardiome Reports 2010 Results (Mar.10)
  
• AMORFIX LIFE SCIENCES TO PRESENT DATA ON ITS PRECLINICAL ASSAY FOR THE DETECTION OF AGGREGATED ABETA IN CSF AT INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES (Mar.9)
  
• CARDIOME TO RELEASE FOURTH QUARTER AND FISCAL 2010 RESULTS (Mar.9)
  
• OncoGenex to Webcast Discussion of Fourth Quarter and Full Year 2010 Financial Results on Thursday, March 10, 2011 (Mar.7)
  
• Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com (Mar.7)
  
• Three MaRS cleantech clients secure angel financing with help from the MaRS angel program (Mar.3)
• Pfizer Canada reaches $50 million milestone in donations of medicine (Mar.3)
  
• MEDIA ADVISORY - Oncolytics Biotech® Inc. to Present at 31st Annual Cowen and Company Healthcare Conference (MAR 3)
• Immunovaccine Announces Issuance of Common Shares to a Consultant (Mar.2)
  
• Oncolytics Biotech® Inc. Receives $7.7 Million from Exercise of Warrants (Mar.1)
• Allon Therapeutics to Present Live, Online at RetailInvestorConferences.com on March 3rd (Feb.28)
  
• BDC among Best Employers for New Canadians (Feb.28)
  
• MaRS client MMB Research closes angel financing (Feb.28)
  
• AMORFIX CLOSES $.5 MILLION PRIVATE PLACEMENT (Feb.28)
  
• Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens (Feb 23)
  
• Oncolytics Biotech® Inc. Announces Completion of Enrollment in Translational Clinical Trial Investigating REOLYSIN® in Patients with Metastatic Colorectal Cancer (Feb.23)
  
• Sanofi Pasteur and International Vaccine Institute Partner Against Dengue (Feb.22)
  
• BDC one of Canada's Best Diversity Employers in 2011 (Feb.22)
• Aeterna Zentaris to Make Presentations on Novel Anticancer Compounds at Upcoming Bio Partnering North America in Vancouver and RBC Capital Markets Healthcare Conference in New York (Feb.22)
• Guelph Hosts Canadian First: Universities Fighting World Hunger Summit (Feb.18)
  
• SEMBIOSYS ANNOUNCES MODIFICATION OF FINANCING TERMS (Feb.18)
  
• Angiotech Pharmaceuticals, Inc. Announces Execution of Settlement and License Termination Agreement With Rex Medical, LP (Feb.18)
  
• Angiotech Announces Acceptance of Plan of Compromise or Arrangement for Presentation at a Meeting of Affected Creditors by the Supreme Court of British Columbia (Feb.18)
  
• CYTOCHROMA INITIATES PHASE 2B STUDY OF CTAP101 CAPSULES IN CHRONIC KIDNEY DISEASE PATIENTS (Feb.17)
• OncoGenex Included in Fast Company Magazine's Top Ten "Most Innovative Companies" in the Biotech Industry (Feb.17)
  
• Tackling Bacterial Infection (Feb.16)
• Oncolytics Biotech® Inc. Announces Start of Enrollment in Randomized Phase II Pancreatic Cancer Study (Feb.16)
• Microbix Further Strengthens Patent Position for LumiSort™ -- its Livestock Semen Sexing Technology (Feb.16)
• FIRST PATIENT ENROLLED IN SECOND PHASE III CLINICAL TRIAL OF UROCIDIN(TM) (Feb.16)
  
• AMORFIX ANNOUNCES THIRD QUARTER FISCAL 2011 RESULTS AND $0.51 MILLION PRIVATE PLACEMENT (Feb.15)
• Vaccinating Cattle to Protect Human Health a Topic for First International One Health Congress (Feb.15)
• Medicago invited to present at the 7th WHO's meeting on evaluation of pandemic influenza prototype vaccines in clinical trials (Feb.15)
• Young Canadian Entrepreneurs Champion Positive Social Change (Feb.15)
• MANUFACTURING INDUSTRIES DEPENDING ON ECONOMY-WIDE UPTURN TO RETURN TO PRE-RECESSION PERFORMANCE (Feb.15)
  
• Oncolytics Biotech® Inc. Meets Primary Endpoint for First Part of U.S. Phase 2 Pancreatic Cancer Clinical Trial (Feb 14)
• Microbix Reports First Quarter Results (Feb 14)
• SEMBIOSYS ENTERS INTO COMMITMENT FOR UP TO $4 MILLION IN FINANCING (Feb 11)
• Angiotech Pharmaceuticals, Inc. Announces Debtor-in-Possession Financing up to $28.0 Million (Feb 11)
  
• Medicago to present at the 13th annual BIO CEO & Investor Conference (Feb10)
• YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results (Feb 10)
• MEDIA ADVISORY - Oncolytics Biotech® Inc. to Present at 13th Annual BIO CEO & Investor Conference (Feb 10)
• Bioniche Life Sciences Inc. Reports Fiscal 2011 Second Quarter Results (Feb10)
• BDC acquires newly issued shares in Prosys Tech Corporation (Feb 10)
• Immunovaccine Provides Corporate Update (Feb 10)
  
• Angiotech Pharmaceuticals, Inc. Announces Agreement with Consenting Noteholders to Extend Certain Deadlines under Support Agreement (Feb 9)
  
• MaRS client Smart Energy Instruments closes angel financing (Feb 9)
  
• Microbix' CEO Statement on Universal Vaccine (Feb 8)
  
• Medicago receives FDA regulatory clearance to initiate U.S. clinical trial for a new influenza vaccine candidate (Feb 8)
  
• OncoGenex Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference (Feb 8)
  
• Immunovaccine Announces Issuance of Common Shares to a Consultant     (Feb 2)
  
• Angiotech Pharmaceuticals, Inc. Announces Effective Date for De-Listing of Common Shares from Toronto Stock Exchange (Feb 2)
  
• BDC one of Montréal's Top Employers (Feb 2)
  
• Toronto scientists Till, McCulloch honoured as fathers of stem cell research on 50th anniversary of groundbreaking discovery that created new field of science (Feb 1)
  
• Medicago reports positive Phase II interim results for its avian flu pandemic vaccine (Feb 1)
  
• WOMEN IN QUEBEC NOW HAVE ACCESS TO PROLIA® (DENOSUMAB) FOR POSTMENOPAUSAL OSTEOPOROSIS (Feb 1)
  
• Angiotech Pharmaceuticals, Inc. Announces U.S. Chapter 15 Filings in Connection with Previously Announced CCAA Proceedings (Jan 31)
  
• Angiotech Pharmaceuticals, Inc. to Pursue Completion of Previously Announced Recapitalization Transaction Through CCAA Proceedings (Jan 28)
  
• Bioniche Life Sciences Inc. Securities Now Trading on the Australian Securities Exchange (ASX) (Jan 28)
  
• Angiotech Pharmaceuticals, Inc. Announces Receipt of Notice of Termination From Rex Medical L.P. (Jan 26)
  
• Ontario start-ups to meet with major Madison Avenue influencers and US investors in NYC (Jan 26)
  
• CANGENE ANNOUNCES CEO IS STEPPING DOWN (Jan 26)
  
• BDC supports 2011 as Year of the Entrepreneur (Jan 25)
  
• CANGENE PLASMA RESOURCES CALIFORNIA WEATHERS EFFECTS OF NEIGHBOURING FIRE (Jan 25)
  
• Oncolytics Biotech® Inc. Receives US$6.8 Million from Exercise of Warrants (Jan 25)
  
• Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease (Jan 25)
  
• $3.5 million for preventing and managing chronic diseases in Québec - The FRSQ, MSSS and Pfizer announce funding for five chronic disease research projects (Jan 24)
  
• Bioniche Life Sciences Inc. Listing on the Australian Securities Exchange (ASX) (Jan 20)
  
• Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs (Jan 19)
  
• Australian Patent Number 2003221575 issued for "TENEURIN C-TERMINAL ASSOCIATION PEPTIDES (TCAP) AND USES THEREOF" (Jan 17)
  
• Oncolytics Biotech® Inc. Announces 2-Arm, Randomized Phase II Pancreatic Cancer Study (Jan 18)
• CO2 Solution Announces Extension of Joint Development Agreement with Codexis (Jan 18)
  
• Microbix Appoints CEO and Chairman of its New Vaccine Joint Venture in China (Jan 18)
  
• SPRYCEL® SHOWS PROMISE AS FIRST LINE THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA (Jan 17)
  
• ANGIOTECH PHARMACEUTICALS ANNOUNCES DELISTING FROM THE NASDAQ STOCK MARKET AND TRANSFER TO OTCQB™ MARKETPLACE (Jan 13)
  
• Angiotech Pharmaceuticals, Inc. Announces Agreement with Consenting Noteholders to Extend Certain Deadlines under Support Agreement (Jan 12)
  
• Medicago selected to collaborate with IDRI on a multimillion dollar grant awarded to IDRI from the US Department of Defense (Jan.11)
  
• Oncolytics Biotech® Inc. Announces Opening of Enrollment in U.S. Phase I Colorectal Cancer Study (Jan 10)
  
• AMORFIX ALZHEIMER'S TEST DETECTS AGGREGATED BETA AMYLOID IN HUMAN CSF (Jan 7)
  
• Pfizer Canada proudly supports ACTI-MENU in the 5/30 Health and Wellness Challenge (Jan 6)
  
• Microbix' CEO Sells Shares to Invest in China Vaccine Joint Venture (Jan 6)
  
• ANGIOTECH PHARMACEUTICALS ANNOUNCES NOTICE OF DELISTING FROM THE NASDAQ STOCK MARKET (Jan 5)
  
• Immunovaccine to Present at Biotech Showcase™ 2011 (Jan 5)
  
• Medicago announces Publication of its Phase I Study with its Pandemic H5N1 Influenza Virus-Like Particle (VLP) Vaccine Candidate (Jan 5)
  
• Immunovaccine Announces Issuance of Common Shares to a Consultant (Jan 4)
  
• Bioniche Announces Reorganization of Leadership Team (Jan 4)
  
• AMORFIX ANNOUNCES PRESENTATION AND WEBCAST AT THE BIOTECH SHOWCASE 2011 CONFERENCE (Jan 4)
  
• ADVANCED ORTHOMOLECULAR RESEARCH ACQUIRES BELLUS HEALTH'S CANADIAN SUBSIDIARY OVOS NATURAL HEALTH  (Jan 4)